Targeted therapy for liver cancer: Updated review in 2012

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1062-1072

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brivanib; Complete remission; Everolimus; Hepatocellular carcinoma; Molecular targeted agent; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; AXITINIB; BRIVANIB; CISPLATIN; DECARBOXYPROTHROMBIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; GELATINASE A; GELATINASE B; INTERFERON; LENVATINIB; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ORANTINIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN; SORAFENIB; TEMSIROLIMUS; TIGATUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ABLATION THERAPY; ANGIOGENESIS; ANOREXIA; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84872593823     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096112091062     Document Type: Review

References (59)

1. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7 (10), 3129-3140.
2. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359 (4), 378-390.
3. Cheng, A. L.; Kang, Y. K.; Chen, Z.; Tsao, C. J.; Qin, S.; Kim, J. S.; Luo, R.; Feng, J.; Ye, S.; Yang, T. S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W. Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10 (1), 25-34.
4. Bruix, J.; Sherman, M. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53 (3), 1020-1022.
5. Omata, M.; Lesmana, L. A.; Tateishi, R.; Chen, P. J.; Lin, S. M.; Yoshida, H.; Kudo, M.; Lee, J. M.; Choi, B. I.; Poon, R. T.; Shiina, S.; Cheng, A. L.; Jia, J. D.; Obi, S.; Han, K. H.; Jafri, W.; Chow, P.; Lim, S. G.; Chawla, Y. K.; Budihusodo, U.; Gani, R. A.; Lesmana, C. R.; Putranto, T. A.; Liaw, Y. F.; Sarin, S. K. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 2010, 4 (2), 439-474.
6. Kudo, M.; Izumi, N.; Kokudo, N.; Matsui, O.; Sakamoto, M.; Nakashima, O.; Kojiro, M.; Makuuchi, M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 2011, 29 (3), 339-364.
7. Kudo, M.; Ueshima, K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010, 78(Suppl 1), 154-166.
8. Murata, K.; Suzuki, H.; Okano, H.; Oyamada, T.; Yasuda, Y.; Sakamoto, A. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int. J. Oncol. 2010, 36 (1), 161-170.
9. Ueshima, K.; Kudo, M.; Takita, M.; Nagai, T.; Tatsumi, C.; Ueda, T.; Kitai, S.; Ishikawa, E.; Yada, N.; Inoue, T.; Hagiwara, S.; Minami, Y.; Chung, H.; Sakurai, T. Des-gammacarboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig. Dis. 2011, 29 (3), 321-325.
10. Kudo, M. Signaling pathway and molecular targeted therapy for hepatocellular carcinoma. Dig. Dis. 2011, 29, 289-302.
11. Spangenberg, H. C.; Thimme, R.; Blum, H. E. Targeted therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2009, 6 (7), 423-432.
12. Kudo, M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. J. Gastroenterol. Hepatol. 2010, 25, 439-452.
13. Kudo, M.; Okanoue, T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007, 72(Suppl 1), 2-15.
14. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
15. Villanueva, A.; Toffanin, S.; Llovet, J. M. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol. 2008, 20 (4), 444-453.
16. Sahin, F.; Kannangai, R.; Adegbola, O.; Wang, J.; Su, G.; Torbenson, M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 2004, 10 (24), 8421-8425.
17. Schumacher, G.; Oidtmann, M.; Rueggeberg, A.; Jacob, D.; Jonas, S.; Langrehr, J. M.; Neuhaus, R.; Bahra, M.; Neuhaus, P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol. 2005, 11 (10), 1420-1425.
18. Semela, D.; Piguet, A. C.; Kolev, M.; Schmitter, K.; Hlushchuk, R.; Djonov, V.; Stoupis, C.; Dufour, J. F. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 2007, 46 (5), 840-848.
19. Sieghart, W.; Fuereder, T.; Schmid, K.; Cejka, D.; Werzowa, J.; Wrba, F.; Wang, X.; Gruber, D.; Rasoul-Rockenschaub, S.; Peck-Radosavljevic, M.; Wacheck, V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83 (4), 425-432.
20. Zhou, L.; Huang, Y.; Li, J.; Wang, Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol. 2010, 27 (2), 255-261.
21. Chen, J. S.; Wang, Q.; Fu, X. H.; Huang, X. H.; Chen, X. L.; Cao, L. Q.; Chen, L. Z.; Tan, H. X.; Li, W.; Bi, J.; Zhang, L. J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol. Res. 2009, 39 (2), 177-186.
22. Villanueva, A.; Chiang, D. Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; Battiston, C.; Van Laarhoven, S.; Fiel, M. I.; Di Feo, A.; Hoshida, Y.; Yea, S.; Toffanin, S.; Ramos, A.; Martignetti, J. A.; Mazzaferro, V.; Bruix, J.; Waxman, S.; Schwartz, M.; Meyerson, M.; Friedman, S. L.; Llovet, J. M. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135 (6), 1972-1983, 1983 e1971-1911.
23. Treiber, G. mTOR inhibitors for hepatocellular cancer: a forwardmoving target. Expert Rev. Anticancer Ther. 2009, 9 (2), 247-261.
24. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18 (1), 4-25.
25. Griffioen, A. W.; Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52 (2), 237-268.
26. Harper, S. J.; Bates, D. O. VEGF-A splicing: the key to antiangiogenic therapeutics? Nat. Rev. Cancer 2008, 8 (11), 880-887.
27. Fernandez, M.; Semela, D.; Bruix, J.; Colle, I.; Pinzani, M.; Bosch, J. Angiogenesis in liver disease. J. Hepatol. 2009, 50 (3), 604-620.
28. Schoenleber, S. J.; Kurtz, D. M.; Talwalkar, J. A.; Roberts, L. R.; Gores, G. J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br. J. Cancer 2009, 100 (9), 1385-1392.
29. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8 (8), 592-603.
30. Batchelor, T. T.; Sorensen, A. G.; di Tomaso, E.; Zhang, W. T.; Duda, D. G.; Cohen, K. S.; Kozak, K. R.; Cahill, D. P.; Chen, P. J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M. M.; Plotkin, S.; Drappatz, J.; Louis, D. N.; Ivy, P.; Scadden, D. T.; Benner, T.; Loeffler, J. S.; Wen, P. Y.; Jain, R. K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007, 11 (1), 83-95.
31. El-Assal, O. N.; Yamanoi, A.; Ono, T.; Kohno, H.; Nagasue, N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 2001, 7 (5), 1299-1305.
32. Poon, R. T.; Ng, I. O.; Lau, C.; Yu, W. C.; Fan, S. T.; Wong, J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 2001, 182 (3), 298-304.
33. Huynh, H.; Ngo, V. C.; Fargnoli, J.; Ayers, M.; Soo, K. C.; Koong, H. N.; Thng, C. H.; Ong, H. S.; Chung, A.; Chow, P.; Pollock, P.; Byron, S.; Tran, E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14 (19), 6146-6153.
34. Bhide, R. S.; Lombardo, L. J.; Hunt, J. T.; Cai, Z. W.; Barrish, J. C.; Galbraith, S.; Jeyaseelan, R., Sr.; Mortillo, S.; Wautlet, B. S.; Krishnan, B.; Kukral, D.; Malone, H.; Lewin, A. C.; Henley, B. J.; Fargnoli, J. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther. 2010, 9 (2), 369-378.
35. Raoul, J. L.; Finn, R. S.; Kang, Y. K.; Park, J. W.; Harris, R.; Coric, V.; Donica, M.; Walters, I. An open-label phase II study of first-and second-line treatment with Brivanib in patients with hepatocellular carcinoma (HCC). J. Clin. Oncol. 2009, 26 (Suppl; Abstr 4577).
36. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407 (6801), 249-257.
37. Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl 1), 2-10.
38. Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008, 122, 644-671.
39. Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008, 14 (17), 5459-5465.
40. Summary of vital statistics annual report (round number). issued 2006, by the Ministry of health, Labour and Welfare, Available from: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/ nengai06/index.html.
41. Llovet, J. M.; Di Bisceglie, A. M.; Bruix, J.; Kramer, B. S.; Lencioni, R.; Zhu, A. X.; Sherman, M.; Schwartz, M.; Lotze, M.; Talwalkar, J.; Gores, G. J. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 2008, 100 (10), 698-711.
42. Llovet, J. M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet 2003, 362 (9399), 1907-1917.
43. Makuuchi, M.; Kokudo, N.; Arii, S.; Futagawa, S.; Kaneko, S.; Kawasaki, S.; Matsuyama, Y.; Okazaki, M.; Okita, K.; Omata, M.; Saida, Y.; Takayama, T.; Yamaoka, Y. Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008, 38 (1), 37-51.
44. Yamaguchi, R.; Yano, H.; Iemura, A.; Ogasawara, S.; Haramaki, M.; Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28 (1), 68-77.
45. Poon, R. T.; Ho, J. W.; Tong, C. S.; Lau, C.; Ng, I. O.; Fan, S. T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004, 91 (10), 1354-1360.
46. Glen, H.; Boss, D.; Morrison, R.; Roelvink, M.; Wanders, J.; Mazur, A. A phase I study of E7080 in patients with advanced malignancies. J. Clin. Oncol. 26 (Suppl May 20), abstr 3526.
47. Nemunaitis, J.; Senzer, N.; Kurzrock, R.; Ng, C.; Das, A.; Atienza, R. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26 (Suppl May 20), abstr 14583.
48. Yamada, K.; Hirata, T.; Fujiwara, Y.; Nokihara, H.; Yamamoto, N.; Yamada, Y. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26 (Suppl May 20), abstr 3527.
49. Sherman, M.; Mazzaferro, V.; Amadori, D.; Seitz, J.; Moscovici, M.; Shan, M.; Nadel, A.; Llovet, J. M.; Bruix, J. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J. Clin. Oncol. 2008, 26(Suppl), abstr 4584 (2008 ASCO Annual Meeting).
50. Faivre, S.; Raymond, E.; Boucher, E.; Douillard, J.; Lim, H. Y.; Kim, J. S.; Zappa, M.; Lanzalone, S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M. J.; Cheng, A. L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009, 10 (8), 794-800.
51. Zhu, A. X.; Sahani, D. V.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O. A.; Sindhwani, V.; Blaszkowsky, L. S.; Yoon, S. S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J. W.; Kwak, E. L.; Hezel, A. F.; Miksad, R.; Abrams, T. A.; Enzinger, P. C.; Fuchs, C. S.; Ryan, D. P.; Jain, R. K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27 (18), 3027-3035.
52. Thomas, M. B.; Chadha, R.; Glover, K.; Wang, X.; Morris, J.; Brown, T.; Rashid, A.; Dancey, J.; Abbruzzese, J. L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110 (5), 1059-1067.
53. Philip, P. A.; Mahoney, M. R.; Allmer, C.; Thomas, J.; Pitot, H. C.; Kim, G.; Donehower, R. C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005, 23 (27), 6657-6663.
54. Zhu, A. X.; Stuart, K.; Blaszkowsky, L. S.; Muzikansky, A.; Reitberg, D. P.; Clark, J. W.; Enzinger, P. C.; Bhargava, P.; Meyerhardt, J. A.; Horgan, K.; Fuchs, C. S.; Ryan, D. P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110 (3),581-589.
55. Abou-Alfa, G. K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Douillard, J. Y.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L. B. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24 (26), 4293-4300.
56. Toh, H.; Chen, P. J.; Carr, B. I.; Knox, J. J.; Gill, S.; Steinberg, J.; Carlson, D. M.; Qian, J.; Qin, Q.; Yong, W. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J. Clin. Oncol. 2009, 27, 15s (suppl; Abstr 4581).
57. Siegel, A. B.; Cohen, E. I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J. J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J.; Christos, P.; Mazumdar, M.; Popa, E.; Brown, R. S. Jr.; Rafii, S.; Schwartz, J. D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008, 26 (18), 2992-2998.
58. O'Dwyer, P. J.; Giantonio, B. J.; Levy, D. E.; Kauh, J. S.; Fitzgerald, D. B.; Benson, A. B. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J. Clin. Oncol. 2006, 24, 18S (Suppl; Abstr 4143).
59. Ramanathan, R. K.; Belani, C. P.; Singh, D. A.; Tanaka, M.; Lenz, H. J.; Yen, Y.; Kindler, H. L.; Iqbal, S.; Longmate, J.; Mack, P. C.; Lurje, G.; Gandour-Edwards, R.; Dancey, J.; Gandara, D. R. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 2009, 64 (4), 777-783.